URML-3881, a Novel MEK Inhibitor for the Treatment of Cancers

Provided herein, are compounds, compositions, and methods of treatment of cancers using an inhibitor of MAPK/ERK Kinase (MEK), in particular hydrazine derivatives.

URV Reference Number: 6-18073
Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Scott Catlin
Associate Vice President
University of Rochester
585-2766-600
scott_catlin@urmc.rochester.edu
Inventors:
Richard Moore
Rakesh Singh
Rachael Turner
Kyu Kwang Kim
Negar Khazan
Keywords: